Abstract
Background: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been used for treatment of peritoneal metastasis of gastric cancer (PM GC) in combination with systemic therapy. While randomized control trials are still lacking, observational studies have shown that PIPAC can potentially prolong survival and support tumor regression. Commonly, PIPAC is performed alternating with systemic chemotherapy with two-week intervals in between. Vascular endothelial growth factor receptor-2 (VEGFR2-receptor antagonist ramucirumab, often in combination with paclitaxel, is a second-line therapy for GC, and has been suspected to enhance side effects of chemotherapy, including wound healing disorders.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
